Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
27.35
+0.02 (0.07%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Arcutis Biotherapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $34.63. The average 1-year stock price forecast is 26.62% higher than the current stock price, while the lowest is $33 (+20.66%) and the highest is $36 (+31.63%).

Price Target: $34.63 (+26.62%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$33$34.63$35$36
Change+20.66%+26.62%+27.97%+31.63%

Analyst Ratings

The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy555555
Buy222222
Hold111111
Sell000000
Strong Sell000000
Total888888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Buy
Reiterates
$35
BuyReiterates$35+27.97%Jul 17, 2026
Mizuho Securities
Mizuho Securities
Buy
Reiterates
$35
BuyReiterates$35+27.97%Jul 15, 2026
Unknown Analyst
Jefferies
No rating
Jefferies
Buy
Maintains
$35
BuyMaintains$35+27.97%Jul 9, 2026
Needham
Needham
Buy
Maintains
$36
BuyMaintains$36+31.63%Jun 30, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$34
BuyReiterates$34+24.31%May 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
500.09M
from 376.07M
Increased by 32.98%
Revenue Next Year
647.23M
from 500.09M
Increased by 29.42%
EPS This Year
0.18
from -0.13
EPS Next Year
1.13
from 0.18
Increased by 541.50%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-3.69M59.61M196.54M376.07M500.09M
Revenue Growth
--1,517.09%229.74%91.34%32.98%
Gross Profit
-2.93M54.62M177.41M339.38M452.58M
Gross Margin
-79.54%91.63%90.27%90.24%90.50%
Operating Income
-206.53M-301.63M-241.10M-128.40M-12.23M25.15M
Net Income
-206.36M-311.46M-262.14M-140.04M-16.14M18.54M
EPS
-----0.130.18
Forward PE
----76.62154.81
Free Cash Flow
-102.77M-195.81M-152.09M-72.90M-15.70M44.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High511.4M
Avg500.1M
Low490.6M

Revenue Growth

Revenue Growth202620272028
High
36.0%
Avg
33.0%
Low
30.5%

EPS Forecast

EPS202620272028
High0.33
Avg0.18
Low-0.05

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-